



overall yield from **1** and **7**, respectively, a result which also provides chemical confirmation of the position of substitution.



Specific activation of the  $\beta'$  position for metalation by the amide is indicated by the fact that cyclohexene is not metalated under similar conditions and that similar dimetalations of allyl and cyclopropyl carbinols generally require much more forcing conditions.<sup>5</sup>

Dimetalations of  $\alpha,\beta$ -unsaturated secondary amides which lack a  $\beta'$  hydrogen have been reported to occur with proton loss from the  $\gamma$  carbon, a result which is consistent with the behavior of other  $\alpha,\beta$ -unsaturated carbonyl derivatives.<sup>6,7</sup> Metalation of an  $\alpha,\beta$ -unsaturated carbonyl system at the  $\beta'$  position seems to be preceded only by formation of a transient intermediate for a case in which  $\gamma$  protons are not present. Kauffmann et al. have found that *N,N*-diisopropyl-2-methylpropenamamide undergoes allylic metalation prior to either self-addition or in situ addition to azobenzene on treatment with lithium diisopropylamide at  $-60^\circ\text{C}$ .<sup>8,9</sup> We have found that *N,N*-dimethylcyclohexenecarboxamide on treatment with *sec*-butyllithium-tetramethylethylenediamine under conditions for the metalation of **1** gives a mixture of products which appear to result from the expected additions and  $\gamma$  metalations. We also observe that *N*-methyl-2,3-dimethyl-2-butenamide appears to undergo substitution at more than one methyl group on treatment with *sec*-butyllithium-tetramethylethylenediamine at  $-78^\circ\text{C}$  in tetrahydrofuran and subsequent treatment with benzophenone.

In summary, we have found that directed lithiation and electrophilic substitution can be achieved selectively at the  $\beta'$  position of  $\alpha,\beta$ -unsaturated secondary amides in the presence of  $\gamma$  and  $\beta$  protons. This result is useful for achieving carbon-carbon bond formation at a site in  $\alpha,\beta$ -unsaturated carbonyl systems which has not been previously recognized as readily available for substitution. Moreover, the demonstration of a convenient, selective, and novel, directed metalation in a nonaromatic system by a group which is available for subsequent transformations could lead to development of a number of new synthons. Investigation of the apparent role of the amide as a strong complexing agent in directed metalations, extensions of other functionalities, and possibilities for more remote metalations are under further study.

**Acknowledgment.** We are grateful to the National Institutes of Health-Institute of General Medicine for support of this work.

## References and Notes

- For summaries of information on directed metalations of aromatic systems see J. M. Mallan and R. L. Bebb, *Chem. Rev.*, **69**, 693 (1969); M. Schlosser, "Struktur und Reaktivität polarer Organometalle," Springer-Verlag, West Berlin, 1973, p 143; D. W. Slocum and D. I. Sugarman, *Adv. Chem. Ser.*, **No. 130**, 222-247 (1974); H. P. Abicht and K. Issleib, *Z. Chem.*, **17**, 1 (1977). For a complete review of metalations at formally  $sp^2$  carbon, see H. W. Gschwend and H. R. Rodriguez, *Org. React.*, **26**, 1-361 (1979).
- W. H. Puterbaugh and C. R. Hauser, *J. Org. Chem.*, **29**, 853 (1964).
- P. Beak and R. A. Brown, *J. Org. Chem.*, **44**, 4463 (1979).
- For cases involving secondary and tertiary amides as useful "ortho" directors in aromatic systems, see J. J. Fitt and H. W. Gschwend, *J. Org. Chem.*, **41**, 4029 (1976); J. E. Baldwin and K. W. Bair, *Tetrahedron Lett.* 2559 (1978); S. O. de Silva and V. Snieckus, *ibid.*, 5103 (1978); S. O. de Silva, I. Ahmad, and V. Snieckus, *ibid.*, 5107 (1978); A. I. Meyers and K. Lutomski, *J. Org. Chem.*, **44**, 4464 (1979); M. Watanabe and V. Snieckus, *J. Am. Chem. Soc.*, **102**, 1457 (1980).
- In general, reactions at least at  $0^\circ\text{C}$  and in hydrocarbon solvents are used:

- R. M. Carlson, *Tetrahedron Lett.*, 111 (1978); G. W. Klumpp, M. Kool, M. Schakel, R. F. Schmitz, and C. Boutkan, *J. Am. Chem. Soc.*, **101**, 7065 (1979).
- J. F. Wolfe, G. B. Trimitsis, and D. R. Morris, *J. Org. Chem.*, **34**, 3263 (1969).
- A. Wu and V. Snieckus, *Tetrahedron Lett.*, 2057 (1975); J. A. Oakleaf; M. T. Thomas, A. Wu, and V. Snieckus, *ibid.*, 1645 (1978).
- W. Bannwarth, R. Eidenschink, and T. Kauffmann, *Angew. Chem., Int. Ed. Engl.*, **13**, 468 (1974).
- NOTE ADDED IN PROOF: H. W. Gschwend independently has observed  $\beta'$  metalation of methyl acrylamides: private communication, March 26, 1980.



Peter Beak,\* Dale J. Kempf

Roger Adams Laboratory, University of Illinois  
Urbana, Illinois 61801  
Received March 6, 1980

## Antitumor Agents. Synthesis of Novel *cis*-Palladium Complexes and Their Action on Supercoiled DNA

Sir:


In 1969 Rosenberg et al. reported that *cis*-dichlorodiammineplatinum(II) (**1**) was the potential antitumor metal chelate;<sup>1</sup> currently **1** has worldwide application in the treatment of cancer.<sup>1,2</sup> However, owing to its severe nephrotoxicity, various analogues have been synthesized by ligand modification<sup>3</sup> to circumvent this limitation. In contrast to these cytotoxic platinum complexes, the palladium analogues were reported to be marginally active<sup>4</sup> and more recently demonstrated to be active against Landschutz ascites (in vitro and in vivo) and Sarcoma 180 systems in anticancer screening.<sup>5</sup> The antitumor properties of several related *cis*-(amine)<sub>2</sub>PtX<sub>2</sub> complexes and the dramatic inactivity of the corresponding *trans* isomer have been shown throughout initial screening and clinical trials. To extend the ligand framework in these antitumor agents, we recently reported *trans*-**3**,<sup>6</sup> which possesses structural similarity to **2** but has two *trans*  $\sigma$ -carbon-palladium bonds. We herein report the synthesis of the stable *cis*-or-



ganometallic reagent **4**, which contains two *cis*  $\sigma$ -palladium-carbon bonds making up a novel [5.5.5] fused-ring system<sup>7</sup> and has the ability to nick supercoiled DNA at low concentrations.

Treatment of 6,6'-dibromo-2,2'-bipyridyl with excess *n*-butyllithium in THF at  $-100^\circ\text{C}$  gave the dilithio intermediate, which upon treatment with *N,N*-dimethylformamide gave 6,6'-diformyl-2,2'-bipyridyl;<sup>11</sup> mp 236-237  $^\circ\text{C}$ . Reduction with sodium borohydride in absolute methanol gave the diol, which upon treatment with redistilled thionyl chloride afforded (45% overall) **5**: mp 157-158  $^\circ\text{C}$ . When a mixture of **5**, diethyl malonate, and anhydrous potassium carbonate in DMF was stirred at  $25^\circ\text{C}$  for 12 h, the desired bis adduct **6**<sup>12</sup> [mp 55-56

°C; 35%, NMR (200 MHz, CD<sub>2</sub>Cl<sub>2</sub>)  $\delta$  1.22 (t,  $J = 7.3$  Hz, CH<sub>3</sub>, 12 H), 3.45 (d,  $J = 7.7$  Hz, py CH<sub>2</sub>, 4 H), 4.15 (m, CH<sub>2</sub>, 8 H), 4.22 (t,  $J = 7.7$  Hz, CH, 2 H), 7.18 (d,  $J = 7.6$  Hz, 5-py H, 2 H), 7.70 (dd,  $J = 7.6, 7.8$  Hz, 4-py H, 2 H), 8.24 (d,  $J = 7.8$  Hz, 3-py H, 2 H); MS  $m/e$  500 ( $M^+$  17.0); IR (CHCl<sub>3</sub>) 1738 (C=O) cm<sup>-1</sup> and a monoadduct **7** [1.3%; MS  $m/e$  376 ( $M^+$  11.9)] were isolated. An anhydrous ethanol solution of sodium ethoxide was added dropwise to a THF solution of PdCl<sub>2</sub>(PhCN)<sub>2</sub> and **6**. After 12 h at 25 °C the resultant con-



centrate was recrystallized from benzene and diethyl ether to give (25%) complex **4**, as yellow needles:<sup>12</sup> mp 230–232 °C dec; NMR (CD<sub>2</sub>Cl<sub>2</sub>)  $\delta$  1.21 (t,  $J = 7.2$  Hz, CH<sub>3</sub>, 12 H), 3.90 (s, py CH<sub>2</sub>, 4 H), 4.14 (m, CH<sub>2</sub>CH<sub>3</sub>, 8 H), 7.49 (d,  $J = 7.8$  Hz, 5-py H, 2 H), 7.64 (d,  $J = 7.8$  Hz, 3-py H, 2 H), 7.91 (t,  $J = 7.8$  Hz, 4-py H, 2 H); IR (CHCl<sub>3</sub>) 1729 (C=O) cm<sup>-1</sup>. In addition, mass spectrum of **4** exhibited a parent-ion isotope pattern centered at  $m/e$  604 in accord with the proposed structure. A second complex was isolated (5.5%), recrystallized (benzene–petroleum ether), and spectrally shown to be **8**:<sup>12</sup> mp 187–189 °C dec.

Evidence supportive of the [5.5.5] system in **4** is based on spectral data. In view of the sharp NMR spectrum for **7**, palladium is diamagnetic and thus possesses a (distorted) square planar configuration.<sup>13</sup> The completely symmetrical configuration is confirmed by the NMR first-order pattern and the syn orientation of the bipyridyl moiety is indicated by the pyridine-H<sub>3</sub> chemical shift ( $\delta$  7.64). This value of  $\delta$  7.64 is in accord with an anticipated upfield shift (~1 ppm)<sup>14</sup> caused by the anti (**6**,  $\delta_{H_3}$  8.24) to syn conformational change coupled with a downfield shift (~0.3 ppm) resultant to metal–N coordination.<sup>15</sup> The 16-line multiplet at  $\delta$  4.14 for the ethyl methylene protons is caused by the diastereotopic environment imposed by the rigid metal-centered ring system.

As a basis for future investigations, it was of interest to learn if these new cis palladium reagents, which replaced the metal–halide bonds in **1** with metal–carbon bonds, would introduce lesions into purified DNA. We have used superhelical phage PM2 DNA in an assay system<sup>16</sup> based on filtration through nitrocellulose filters, in which denatured DNA or DNA containing single-stranded regions is selectively retained. Preliminary investigations have focused on determining if during the course of action of **4** single-stranded nicks in DNA are produced. As shown in Table I, it appears that one mechanism of action of **4** results in the creation of nicks of DNA. The cis geometry in **4** is obviously critical since the corresponding trans compound **3** is ineffective. The initial ligand **6** is also inactive. That only the cis form is active is not unreasonable in light of the results obtained on studies of the platinum complexes, in which only the cis form is effective as an antitumor drug.<sup>1,2</sup> An observation not depicted in Table I is that the nicking activity of **4** is dependent on temperature (twofold decrease at 25 °C) and the time of reaction.

In conclusion, it appears that selected cis palladium organometallics may act in a manner similar to that of the

**Table I.** Supercoiled Phage PM2 DNA Nicked by Palladium Compounds<sup>a</sup>

concn, $\mu$ M of added compd	nicks introduced, fmol		
	<i>cis</i> - <b>4</b>	<i>trans</i> - <b>3</b>	
7	10	2	
14	36	2	
22	80	2	
40			<2

<sup>a</sup> Reaction mixtures (0.05 mL) contained 130 fmol of PM2 [<sup>3</sup>H]DNA molecules, Tris (25 mM), pH 7.5, MgCl<sub>2</sub> (10 mM), and the palladium compound as indicated and then were incubated at 37 °C for 5 min. Procedures for the detection of activity and quantification of nicks introduced by added palladium compounds have been previously described.<sup>16</sup>

known intercalating antitumor platinum drugs. Currently, we are investigating ligand and metal modifications and their subsequent activity with DNA.

## References and Notes

- (1) (a) Rosenberg, B.; Van Camp, L.; Trosko, J. E.; Mansour, V. H. *Nature (London)* **1969**, *222*, 385. (b) Rosenberg, B.; Van Camp, L. *Cancer Res.* **1970**, *30*, 1799. (c) Rosenberg, B. *Platinum Met. Rev.* **1971**, *15*, 42. (d) Rosenberg, B. *Naturwissenschaften* **1973**, *60*, 399. (e) Also see: Hill, J. M.; Loeb, E.; MacLellan, A.; Hill, N. O.; Khan, A.; King, J. J. *Cancer Chemother. Rep.* **1975**, *59*, 647. Lippard, S. J. *Acc. Chem. Res.* **1978**, *11*, 211.
- (2) See: *J. Clin. Hematol. Oncol.* **1977**, *7*; *Science* **1976**, *192*, 774. Connors, T. A. *Platinum Met. Rev.* **1973**, *17*, 98.
- (3) Meischen, S. J.; Gale, G. R.; Lake, L. M.; Frangakis, C. J.; Rosenblum, M. G.; Walker, Jr., E. M.; Atkins, L. M.; Smith, A. B. *J. Natl. Cancer Inst.* **1976**, *57*, 841. Ridgeway, H. J.; Speer, R. J.; Hall, L. M.; Stewart, D. P.; Newman, A. D.; Hill, J. M. *J. Clin. Hematol. Oncol.* **1977**, *7*, 220. Connors, T. A.; Jones, M.; Ross, W. C. J.; Braddock, P. D.; Khokhar, A. R.; Tobe, M. L. *Chem.-Biol. Interact. (London)* **1972**, *5*, 415.
- (4) Cleare, M. J.; Hoeschele, J. D. *Bioinorg. Chem.* **1973**, *2*, 187.
- (5) (a) Graham, R. D.; Williams, D. R. *J. Inorg. Nucl. Chem.* **1971**, *41*, 1245. (b) Also see Kirschner, S.; Wei, Y.-K.; Francis, D.; Bergman, J. G. *J. Med. Chem.* **1966**, *9*, 369.
- (6) Newkome, G. R.; Kawato, T. *Inorg. Chim. Acta* **1979**, *37*, L841.
- (7) In the course of diorthometalation studies, *N,N'*-dimethyl-*N,N'*-bis(*o*-bromobenzyl)ethylenediamine with anhydrous iron(II) chloride gave a distorted tetrahedral [5.5.5]-fused-ring system containing a pivotal ferrous ion.<sup>8</sup> However, when PhCH<sub>2</sub>(Me)N(CH<sub>2</sub>)<sub>n</sub>N(Me)CH<sub>2</sub>Ph (I,  $n = 2$  or 3) was treated with Na<sub>2</sub>PdCl<sub>4</sub> (or Na<sub>2</sub>PtCl<sub>4</sub>), the intermediate bidentate bis N complex underwent internal cyclometalation to give a *monoorthometalated compound*; only when  $n = 3$  does bisorthometalation occur (i.e., to the [5.6.5] system). The distorted square planar [5.5.5] fused system for I ( $n = 2$ ) could not be prepared as explained on steric grounds.<sup>9</sup> In stark contrast to these results, the literature abounds in [5.5.5] complexes derived from nitrogen, oxygen, and/or sulfur donor ligands.<sup>10</sup>
- (8) Küpper, F. W. *J. Organomet. Chem.* **1968**, *13*, 219.
- (9) Clerici, M. G.; Shaw, B. L.; Weeks, B. J. *Chem. Soc., Chem. Commun.* **1973**, 516. Duff, J. M.; Shaw, B. L. *J. Chem. Soc., Dalton Trans.* **1972**, 2219.
- (10) Selected examples: House, D. A.; Curtis, N. F. *J. Am. Chem. Soc.* **1964**, *86*, 1331. Nakahara, A.; Yamamoto, H.; Matsumoto, H. *Bull. Chem. Soc. Jpn.* **1964**, *37*, 1137. Jones, C. J.; McCleverty, J. A. *J. Chem. Soc. A* **1970**, 2829. Lewis, J.; Wainwright, K. P. *J. Chem. Soc., Chem. Commun.* **1974**, 169. Nikles, D. E.; Powers, M. J.; Urbach, F. L. *Inorg. Chim. Acta* **1979**, *37*, L499.
- (11) Parks, J. E.; Wagner, B. E.; Holm, R. H. *J. Organomet. Chem.* **1973**, *56*, 53.
- (12) Satisfactory analyses were obtained for all new compounds.
- (13) The X-ray crystal structure of both **6** ( $R = CN$ ) and the corresponding palladium complex are in progress and will be published in the full paper: F. Fronczek, LSU.
- (14) Newkome, G. R.; Nayak, A.; Fronczek, F.; Kawato, T.; Taylor, H. C. R.; Meade, L.; Mattice, W. *J. Am. Chem. Soc.* **1979**, *101*, 4472.
- (15) Castellano, S.; Günther, H.; Ebersole, S. *J. Phys. Chem.* **1965**, *69*, 4166. Kramer, Jr., F. A.; West, R. *Ibid.* **1965**, *69*, 673. Spotswood, T. McL.; Tanzer, C. I. *Aust. J. Chem.* **1967**, *20*, 1227. Castellano, S.; Günther, H. *J. Phys. Chem.* **1967**, *71*, 2368.
- (16) Kuhnlein, U.; Penhoet, E. E.; Linn, S. *Proc. Natl. Acad. Sci. U.S.A.* **1976**, *73*, 1169. Kuhnlein, U.; Lee, B.; Penhoet, E. E.; Linn, S. *Nucl. Acids Res.* **1978**, *5*, 951. Kuhnlein, U.; Tsang, S. S.; Edwards, J. *Mutat. Res.* **1979**, *64*, 167.
- (17) On leave from Nagasaki University, Nagasaki, Japan, 1979–1980.
- (18) (a) Department of Chemistry; (b) Department of Biochemistry.

George R. Newkome,<sup>\*,18a</sup> Masayoshi Onishi<sup>17,18a</sup>  
Wallace E. Puckett,<sup>18a</sup> Walter A. Deutsch<sup>18b</sup>

Department of Chemistry, Department of Biochemistry  
Louisiana State University, Baton Rouge, Louisiana 70803

Received February 19, 1980